260 related articles for article (PubMed ID: 37280200)
1. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis.
Gui W; Hole MJ; Molinaro A; Edlund K; Jørgensen KK; Su H; Begher-Tibbe B; Gaßler N; Schneider CV; Muthukumarasamy U; Mohs A; Liao L; Jaeger J; Mertens CJ; Bergheim I; Strowig T; Hengstler JG; Hov JR; Marschall HU; Trautwein C; Schneider KM
Nat Commun; 2023 Jun; 14(1):3304. PubMed ID: 37280200
[TBL] [Abstract][Full Text] [Related]
2. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
Gao RY; Shearn CT; Orlicky DJ; Battista KD; Alexeev EE; Cartwright IM; Lanis JM; Kostelecky RE; Ju C; Colgan SP; Fennimore BP
Mucosal Immunol; 2021 Mar; 14(2):479-490. PubMed ID: 33004979
[TBL] [Abstract][Full Text] [Related]
3. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
4. A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis.
Stumme F; Steffens N; Steglich B; Mathies F; Nawrocki M; Sabihi M; Soukou-Wargalla S; Göke E; Kempski J; Fründt T; Weidemann S; Schramm C; Gagliani N; Huber S; Bedke T
Front Immunol; 2024; 15():1307297. PubMed ID: 38510236
[TBL] [Abstract][Full Text] [Related]
5. PSC, AIH and overlap syndrome in inflammatory bowel disease.
Trivedi PJ; Chapman RW
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):420-36. PubMed ID: 22306055
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
8. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
[TBL] [Abstract][Full Text] [Related]
9. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
10. PSC associated inflammatory bowel disease: a distinct entity.
Beheshti-Maal A; Tamimi A; Iravani S; Memarnejadian A; Sorouri M; Aghdaei HA; Zali MR; Hossein Khannazer N; Vosough M
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):129-139. PubMed ID: 35078376
[TBL] [Abstract][Full Text] [Related]
11. Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.
Fejfar T; Vaňásek T; Hůlek P
Vnitr Lek; 2020; 66(5):287-300. PubMed ID: 32942866
[TBL] [Abstract][Full Text] [Related]
12. Primary sclerosing cholangitis.
Rodriguez HJ; Bass NM
Semin Gastrointest Dis; 2003 Oct; 14(4):189-98. PubMed ID: 14719769
[TBL] [Abstract][Full Text] [Related]
13. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
14. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
16. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
Liwinski T; Hübener S; Henze L; Hübener P; Heinemann M; Tetzlaff M; Hiller MI; Jagemann B; Surabattula R; Leeming D; Karsdal M; Monguzzi E; Schachschal G; Rösch T; Bang C; Franke A; Lohse AW; Schuppan D; Schramm C
Aliment Pharmacol Ther; 2023 Jan; 57(2):224-236. PubMed ID: 36266939
[TBL] [Abstract][Full Text] [Related]
17. Prevotella copri ameliorates cholestasis and liver fibrosis in primary sclerosing cholangitis by enhancing the FXR signalling pathway.
Jiang B; Yuan G; Wu J; Wu Q; Li L; Jiang P
Biochim Biophys Acta Mol Basis Dis; 2022 Mar; 1868(3):166320. PubMed ID: 34896545
[TBL] [Abstract][Full Text] [Related]
18. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
De Muynck K; Heyerick L; De Ponti FF; Vanderborght B; Meese T; Van Campenhout S; Baudonck L; Gijbels E; Rodrigues PM; Banales JM; Vesterhuus M; Folseraas T; Scott CL; Vinken M; Van der Linden M; Hoorens A; Van Dorpe J; Lefere S; Geerts A; Van Nieuwerburgh F; Verhelst X; Van Vlierberghe H; Devisscher L
Hepatology; 2024 Feb; 79(2):269-288. PubMed ID: 37535809
[TBL] [Abstract][Full Text] [Related]
20. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis.
Schaeffer DF; Win LL; Hafezi-Bakhtiari S; Cino M; Hirschfield GM; El-Zimaity H
Dig Dis Sci; 2013 Sep; 58(9):2608-14. PubMed ID: 23670229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
